Zometa in therapy for bone metastases of prostate cancer during androgenic deprivation (Results of Russian multicenter study)

Introduction: Hormonal therapy is the method of choice in treating disseminated prostate cancer. Chronic androgenic suppression causes a reduction in bone mineral density. The most common complications of bone metastases are pathological fractures, spinal cord compression, pain, etc.

Methods: A multicenter study (11 clinics of Russia) assessing the efficacy of Zometa in preventing skeletal complications of bone metastases was conducted in 2004—2005. Zometa was administered intravenously at a dose of 4 mg every 3Р4 weeks with androgenic deprivation. Its objective effect was evaluated in 70 patients. Changes in bone mineral density were evaluated by densitometry.

Results: Complete pain relief was achieved in 73% of the patients; after therapy 86% of the patients had 0—1 WHO activity status score, 97% of the patients had no bone complications. The level of bone resorption marker β-Cross-Laps decreased to the normal values in 51% of the patients.

Conclusion: The study has provided an evidence of the efficacy of Zometa and the necessity of using this drug in complex therapy for bone metastases of prostate cancer.

1. Матвеев Б.П. Клиническая онкоурология. 2003.

2. Давыдов М.И., Аксель Е.М. Злокачественные заболевания в России и странах СНГ в 2003 году. М.; 2004.

3. Coleman R.E. Metastatic bone disease:clinical features,pathophysiology and treatment strategies.Cancer Treat Rev 2001;27:165—76.

4. Cecchini M.G.,Wetterwald A., van der Pluijm G., Thalmann G.N. Molecular and Biological Mechanisms of Bone Metastasis. EAU Update Series 2005;3:214—26.

5. Bogdanos J., Karamanolakis D., Tenta R. et al. Endocrine/paracrine/autocrine survival factor activity of bone micro-environment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton.Endocr Relat Cancer 2003;10(2):279—89.

6. Saad F., Colerman R.E., Cook R. et al. Predictors of clinical outcome in patients with prostate cancer and bone metastases:prognostic significance of fractures and bone markers. Eur Urol Suppl 2006;5(2):55.

7. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19(10):80—100.

8. Berruti A., Dogliotti L., Tucci M. et al. Metabolic bone disease induced by prostate cancer:rationale for the use of bisphosphonates. J Urology 2001;166(6):2023—31.

9. Rosen L.S., Gordon D., Kaminski M. et al. Long-term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complication in patient with advanced multiple mieloma or breast carcinoma. Cancer 2003;98:1735—44.

10. Saad F., Gleason D.M., Murray R. et al.; Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zolendronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96(11): 879—82.

11. Saad F., Gleason D.M., Murray R. et al.; Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zolendronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458—68.

12. Матвеев Б.П., Карякин О.Б., Матвеев В.Б. и др. Зомета в лечении больных распространенным раком предстательной железы (Результаты Российского многоцентрового исследования). Соврем онкол 2004;6(3).

13. Costa L., Demers L.M., Gouveia-Oliveira A. et al. Prospective evaluation of the peptide-bound collagen type I crosslinks N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002;20:850—6.